Home
About Us
Membership
Member Biography

Member Biography

Attaya Suvannasankha, MD

Attaya Suvannasankha, M.D.

Phone: (317) 278-9306
Phone: (317) 944-0920, Patient issues/appointments

980 W. Walnut St.
R3 312
Indianapolis, IN 46202

Faculty appointments

Associate Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Full member, Hematopoiesis & Hematologic Malignancies, Experimental and Developmental Therapeutics

A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple MyelomaCTO-64407564MMY1004

A Phase 1/2 FIH Study of REGN5458 (anti-BCMA x anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple MyelomaCTO-R5458-ONC-1826

A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants with Multiple MyelomaCTO-64007957MMY1004

Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody.ECRO-GSK-BELANTAMAB-EAP

Preclinical Validation of Adjuvant Fingolimod to Increase Efficacy of Proteasome Inhibitors for Treatment of Multiple MyelomaCTO-IUSCCC-0882

PHASE 1B STUDY OF REGN5458 (ANTI-BCMA X ANTICD3 BISPECIFIC ANTIBODY) PLUS OTHER CANCER TREATMENTS FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMACTO-R5458-ONC-2012

A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMACTO-C1071030

A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of Intermediate Fit Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance.CTO-S2209

Longitudinal Multi-Center Chart Review Study and Consortium for Multiple Myeloma (eMMpower) DARA-2552

Headlines & highlights

#ResearchCuresCancer

Support Our Research